Eikon Therapeutics Inc.

02/04/2026 | Press release | Distributed by Public on 02/04/2026 20:59

Initial Statement of Beneficial Ownership (Form 3)

FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
Column Group IV GP, LP
2. Date of Event Requiring Statement (Month/Day/Year)
02/04/2026
3. Issuer Name and Ticker or Trading Symbol
Eikon Therapeutics, Inc. [EIKN]
(Last) (First) (Middle)
1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed (Month/Day/Year)
(Street)
SAN FRANCISCO, CA 94129
6. Individual or Joint/Group Filing (Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 63,691 I See footnote(1)
Common Stock 3,352 I See footnote(2)
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Series A Preferred Stock (3) (3) Common Stock 1,296,629 (3) I See footnote(1)
Series A Preferred Stock (3) (3) Common Stock 44,249 (3) I See footnote(2)
Series A-1 Preferred Stock (4) (4) Common Stock 1,403,568 (4) I See footnote(1)
Series A-1 Preferred Stock (4) (4) Common Stock 47,898 (4) I See footnote(2)
Series C-1 Preferred Stock (5) (5) Common Stock 110,928 (5) I See footnote(1)
Series C-1 Preferred Stock (5) (5) Common Stock 3,785 (5) I See footnote(2)
Series D Preferred Stock (6) (6) Common Stock 688,283 (6) I See footnote(7)
Warrant 02/14/2025 02/14/2030 Common Stock 573,569 $43.59 I See footnote(7)

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Column Group IV GP, LP
1 LETTERMAN DRIVE
BUILDING D, SUITE DM-900
SAN FRANCISCO, CA 94129
X
Column Group IV-A, LP
1 LETTERMAN DRIVE
BUILDING D, SUITE DM-900
SAN FRANCISCO, CA 94129
X
Column Group Opportunity III, LP
1 LETTERMAN DRIVE
BUILDING D, SUITE DM-900
SAN FRANCISCO, CA 94129
X
Column Group Opportunity III GP, LP
1 LETTERMAN DRIVE
BUILDING D, SUITE DM-900
SAN FRANCISCO, CA 94129
X
TCG Opportunity III GP, LLC
1 LETTERMAN DRIVE
BUILDING D, SUITE DM-900
SAN FRANCISCO, CA 94129
X

Signatures

The Column Group IV, LP, by The Column Group IV GP, LP, its general partner, /s/ James Evangelista Attorney-in-Fact 02/04/2026
**Signature of Reporting Person Date
The Column Group IV-A, LP, by The Column Group IV GP, LP, its general partner, /s/ James Evangelista Attorney-in-Fact 02/04/2026
**Signature of Reporting Person Date
The Column Group IV GP, LP, /s/ James Evangelista Attorney-in-Fact 02/04/2026
**Signature of Reporting Person Date
The Column Group Opportunity III, LP, by The Column Group Opportunity GP, LP its general partner, by TCG Opportunity III GP, LLC, its general partner, /s/ James Evangelista Attorney-in-Fact 02/04/2026
**Signature of Reporting Person Date
The Column Group Opportunity GP, LP, by TCG Opportunity III GP, LLC, its general partner, /s/ James Evangelista Attorney-in-Fact 02/04/2026
**Signature of Reporting Person Date
TCG Opportunity III GP, LLC, /s/ James Evangelista Attorney-in-Fact 02/04/2026
**Signature of Reporting Person Date
/s/ James Evangelista, as attorney-in-fact for Tim Kutzkey 02/04/2026
**Signature of Reporting Person Date
/s/ James Evangelista, as attorney-in-fact for Peter Svennilson 02/04/2026
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The shares are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to shares directly held by TCG IV LP. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein.
(2) The shares are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of the TCG IV-A LP and may be deemed to have voting and investment power with respect to shares directly held by the Reporting Person. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV-A LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein.
(3) The Series A Preferred Stock is convertible into Common Stock on a 1-for-7.4578 basis and has no expiration date. Immediately prior to the closing of the Issuer's initial public offering ("IPO"), all shares of Series A Preferred Stock will be converted into shares of Common Stock of the Issuer.
(4) The Series A-1 Preferred Stock is convertible into Common Stock on a 1-for-7.4578 basis and has no expiration date. Immediately prior to the closing of the Issuer's IPO, all shares of Series A-1 Preferred Stock will be converted into shares of Common Stock of the Issuer.
(5) The Series C-1 Preferred Stock is convertible into Common Stock on a 1-for-7.4578 basis and has no expiration date. Immediately prior to the closing of the Issuer's IPO, all shares of Series C-1 Preferred Stock will be converted into shares of Common Stock of the Issuer.
(6) The Series D Preferred Stock is convertible into Common Stock on a 1-for-7.4578 basis and has no expiration date. Immediately prior to the closing of the Issuer's IPO, all shares of Series C-1 Preferred Stock will be converted into shares of Common Stock of the Issuer.
(7) The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP. TCG Opportunity III GP, LLC is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP. Each of TCG Opportunity III GP LP and TCG Opportunity III GP, LLC may be deemed to have voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Peter Svennilson and Tim Kutzkey are the managing members of TCG Opportunity III GP, LLC and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Eikon Therapeutics Inc. published this content on February 04, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on February 05, 2026 at 02:59 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]